6 November 2025 (Thursday) - BTLP-TACT Exercise

I suppose I should really do a BTLP-TACT exercise…  
I had one case – a seventy year old woman supposedly needing FFP for reversal of warfarin therapy.
Her ABO group was indeterminate (cell group A, no reaction in reverse group) but her Rh(D) group was negative.
The antibody screen was weakly positive in cells 1 and 2 so I performed antibody panels.
The IAT and enzyme panels were positive in cells 1, 2 and 3 corresponding with anti-D but not excluding anti-Cw.
Bearing in mind warfarin isn’t recommended for the reversal of warfarin therapy, I didn’t issue any.
I got it right this time…

5 November 2025 (Wednesday) - TACO-Related Fever

Here’s something to think about… back in the day transfusion trigger limits were a *lot* higher than they are these days. We’d give three or four units of blood where these days we’d only give one. And back in the day we were investigating quite a few alleged transfusion reactions which were characterized by post transfusion fevers. We’d do blood cultures… but nothing ever grew.

Were we seeing fevers related to transfusion associated circulatory overload?

4 November 2025 (Tuesday) - Fritsma Factor Newsletter

The Fritsma Factor newsletter appeared in my in-box this morning. As always it’s a rather useful source of information on matters haemostatic…


4 November 2025 (Tuesday) - Information Governance

I did my e-learning on information governance today. Governance… it’s a simple concept really. I have access to confidential information. I only discuss it with those who have a bona-fide reason to know what I know, and I keep my trap shut to everyone else. I make sure that no one could accidentally find out what I know… simple, really.


3 November 2025 (Monday) - A.P.L.

 

Acute promyelocytic leukaemia…  There’s some pictures here and an article about how the condition is best treated here.
 
Oh… Statements 1, 3, and 4 are correct.
The images given show dumbbell-shaped blasts consistent with acute promyelocytic leukemia (APL), a subtype of AML known for its aggressive presentation and high risk of bleeding and/or thrombosis due to coagulopathy. Unlike other AML variants, APL often leads to disseminated intravascular coagulation (DIC), supported by lab findings such as elevated INR, prolonged aPTT, low fibrinogen, and high D-dimer.
Despite its favorable long-term prognosis, APL is a hematologic emergency requiring urgent treatment.  The coagulopathy in APL is primarily driven by tissue factor (TF) released during promyelocyte destruction, triggering excessive activation of the coagulation cascade. With the advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as frontline therapy, APL has become the most curable AML subtype. APL blasts are typically negative for HLA-DR and CD34, distinguishing them from other AML variants.

2 November 2025 (Sunday) - Slide Saturday Challenge

Strange-looking cells…. Obviously derived from basophils… or are they? The nuclei aren’t right.
This is a case of systemic mastocytosis. Here’s some information on the condition.